FFS.. now the hearing has been delayed till the 4th Quarter (originally this quarter).. only benefit here is greater payback if the judgement is ruled in Acrux's favour.. and that share price has already factored in that the appeal will be lost.
Ann: Teva Launches Generic Version of Axiron in United States, page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.73M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 144142 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.1¢ | 100089 | 2 |
View Market Depth
| Last trade - 10.33am 04/09/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable